Abstract
Rationale Cannabis is one of the most commonly used psychoactive substances, and recent reports have shown increased use among women, leading to growing concerns about cannabis use disorder. Some evidence suggests a faster progression to addiction in women, known as the “telescoping effect.” While there is preclinical evidence suggesting biological sex influences cannabinoid effects, human research remains scant. We investigated sex differences in the response to oral tetrahydrocannabinol (THC) in humans.
Methods 55 healthy men and women with prior exposure to cannabis but no history of cannabis use disorder participated in a randomized, placebo-controlled, double-blind, counter-balanced study, receiving a single 10 mg dose of oral THC (dronabinol). Subjective intoxicating effects were assessed by the Visual Analog Scale (VAS) of “high”, psychotomimetic effects by the Clinician-Administered Dissociative Symptoms Scale (CADSS) and Psychotomimetic States Inventory (PSI), cognitive effects by Rey Auditory Verbal Learning Test (RAVLT), and physiologic effects by heart rate. Outcomes were regularly measured on the test day, except for the RAVLT, which was assessed once. Peak differences from baseline were analyzed using a nonparametric method for repeated measures.
Results Oral THC demonstrated significant dose-related effects in psychotomimetic and physiologic domains, but not in cognition. A notable interaction between THC dose and sex emerged concerning the subjective “high” scores, with women reporting heightened sensations (ATS=3.81, num df=1, p=0.05). No other significant effects of sex and THC dose interaction were observed.
Conclusion Oral THC yields similar psychotomimetic and physiologic effects across sexes, but women may experience a pronounced subjective intoxicating effect. Given the escalating accessibility of cannabinoids, further research is needed to identify individual vulnerabilities and facilitate tailored interventions addressing cannabis use disorder.
Competing Interest Statement
J.P.D. has been supported in clinical trials by Jazz Pharmaceuticals, specifically through medication provisions. Additionally, J.P.D. has been a compensated consultant for Boehringer Ingelheim. A.B.N is a member of the Scientific Advisory Committee of Synendos Therapeutics AG, Switzerland.
Clinical Trial
NCT02781519
Funding Statement
This study was funded by National Institute on Drug Abuse (NIDA); grant number 1R21DA038821-01A1. J.P.D. is supported by the grants K23DA052682 and R21DA057240 from the National Institute of Drug Abuse (NIDA). ABN is supported by the National Institute of Health (NIMH) K12DA000167 grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Institutional Review Boards of the VA Connecticut Healthcare System and Yale University School of Medicine.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Clinicaltrials.gov registration: https://clinicaltrials.gov/study/NCT02781519?term=Ranganathan&intr=THC&rank=3
Funding This study was funded by National Institute on Drug Abuse (NIDA); grant number 1R21DA038821-01A1. J.P.D. is supported by the grants K23DA052682 and R21DA057240 from the National Institute of Drug Abuse (NIDA). ABN is supported by the National Institute of Health (NIMH) K12DA000167 grant.
Conflict of interest statement J.P.D. has been supported in clinical trials by Jazz Pharmaceuticals, specifically through medication provisions. Additionally, J.P.D. has been a compensated consultant for Boehringer Ingelheim. A.B.N is a member of the Scientific Advisory Committee of Synendos Therapeutics AG, Switzerland.
Data Availability
All data produced in the present study are available upon reasonable request to the authors